Price (delayed)
$17.99
Market cap
$1.53B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.39
Enterprise value
$1.43B
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab,
There are no recent dividends present for SNDX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.